Uniqure (NASDAQ:QURE) Stock Rating Lowered by BidaskClub

Uniqure (NASDAQ:QURE) was downgraded by research analysts at BidaskClub from a “buy” rating to a “hold” rating in a research note issued on Friday, BidAskClub reports.

Other research analysts have also recently issued research reports about the company. Janney Montgomery Scott restated a “buy” rating on shares of Uniqure in a research note on Tuesday, June 11th. Piper Jaffray Companies set a $80.00 price target on Canopy Growth and gave the stock a “buy” rating in a research note on Friday, April 12th. HC Wainwright set a $73.00 price target on Uniqure and gave the stock a “buy” rating in a research note on Monday, July 8th. Zacks Investment Research upgraded SCHNEIDER ELEC /ADR from a “hold” rating to a “buy” rating and set a $20.00 price target for the company in a research note on Friday, July 5th. Finally, Cantor Fitzgerald boosted their price target on Cerner from $75.00 to $85.00 and gave the stock an “overweight” rating in a research note on Monday, July 8th. One investment analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $78.18.

Uniqure stock opened at $70.32 on Friday. The company has a debt-to-equity ratio of 0.38, a quick ratio of 9.51 and a current ratio of 9.51. The business has a fifty day moving average of $71.87. Uniqure has a 12 month low of $21.98 and a 12 month high of $82.49.

Uniqure (NASDAQ:QURE) last released its earnings results on Monday, April 29th. The biotechnology company reported ($0.74) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.71) by ($0.03). Uniqure had a negative return on equity of 48.90% and a negative net margin of 1,032.06%. The company had revenue of $1.14 million during the quarter, compared to the consensus estimate of $2.00 million. On average, research analysts predict that Uniqure will post -3 EPS for the current year.

In other news, insider Christian Klemt sold 1,546 shares of the business’s stock in a transaction on Tuesday, April 16th. The stock was sold at an average price of $57.18, for a total value of $88,400.28. Following the completion of the transaction, the insider now owns 54,539 shares in the company, valued at $3,118,540.02. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Matthew C. Kapusta sold 8,000 shares of the company’s stock in a transaction on Wednesday, June 19th. The shares were sold at an average price of $77.45, for a total value of $619,600.00. Following the sale, the chief executive officer now owns 409,407 shares of the company’s stock, valued at approximately $31,708,572.15. The disclosure for this sale can be found here. Insiders sold 23,546 shares of company stock valued at $1,556,820 in the last 90 days. Company insiders own 2.91% of the company’s stock.

Institutional investors have recently bought and sold shares of the stock. Harvest Group Wealth Management LLC purchased a new stake in Uniqure during the first quarter valued at $26,000. Pearl River Capital LLC purchased a new stake in Uniqure during the first quarter valued at $32,000. Legal & General Group Plc increased its position in Uniqure by 264.2% during the fourth quarter. Legal & General Group Plc now owns 965 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 700 shares during the last quarter. Financial Gravity Wealth Inc. purchased a new stake in Uniqure during the first quarter valued at $153,000. Finally, First Citizens Bank & Trust Co. purchased a new stake in Uniqure during the second quarter valued at $211,000. Institutional investors own 60.10% of the company’s stock.

Uniqure Company Profile

uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure.

See Also: Earnings Reports

Analyst Recommendations for Uniqure (NASDAQ:QURE)

Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.